当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Imiglucerase-Treated Italian Patients with Gaucher Disease Type 1 or Type 3 had the following Long-term Bone Outcomes: A Sub-study from the Global Cooperative Gaucher Gathering (ICGG) Gaucher Vault

Daou Abdlkri

A rare condition known to cause skeletal symptoms is Gaucher disease. It can progress to aseptic bone necrosis and pathological fractures in the advanced stage. Although enzymatic replacement therapy (ERT) has significantly improved a patient’s quality of life, it has not prevented complications related to the bone. There are very few publications in the literature that have discussed the surgical management of this disorder. The way these patients are handled in orthopedic surgery is very specific.

Most patients with Gaucher illness have moderate and frequently debilitating skeletal indications. The phenotypic diversity of Gaucher disease is well-known, and there are no consistent genotype-phenotype correlations. In Argentina, a public cooperative gathering, Grupo Argentino de Diagnóstico tratamiento de la enfermedad de Gaucher, GADTEG, portrayed consistently extreme sort Gaucher illness signs giving in youth a huge weight of irreversible skeletal sickness. Here utilizing Long-Read Single Atom Ongoing (SMRT) Sequencing of the GBA locus, we show that the RecNciI allele is profoundly common and is related to serious skeletal appearances with beginning in adolescence or in youthful grown-ups. In addition, we described a novel, previously unknown GBA variants.